Cargando…

Liposomal delivery of gene therapy for ovarian cancer: a systematic review

OBJECTIVE: To systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer. METHODS: An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Jin Sung, Chow, Ryan, Kim, Helena, Lieu, Toney, Xiao, Maria, Kim, Sunny, Matuszewska, Kathy, Pereira, Madison, Nguyen, David Le, Petrik, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464441/
https://www.ncbi.nlm.nih.gov/pubmed/37612696
http://dx.doi.org/10.1186/s12958-023-01125-2
_version_ 1785098471471054848
author Son, Jin Sung
Chow, Ryan
Kim, Helena
Lieu, Toney
Xiao, Maria
Kim, Sunny
Matuszewska, Kathy
Pereira, Madison
Nguyen, David Le
Petrik, Jim
author_facet Son, Jin Sung
Chow, Ryan
Kim, Helena
Lieu, Toney
Xiao, Maria
Kim, Sunny
Matuszewska, Kathy
Pereira, Madison
Nguyen, David Le
Petrik, Jim
author_sort Son, Jin Sung
collection PubMed
description OBJECTIVE: To systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer. METHODS: An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion. RESULTS: The search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1). CONCLUSION: Liposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12958-023-01125-2.
format Online
Article
Text
id pubmed-10464441
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104644412023-08-30 Liposomal delivery of gene therapy for ovarian cancer: a systematic review Son, Jin Sung Chow, Ryan Kim, Helena Lieu, Toney Xiao, Maria Kim, Sunny Matuszewska, Kathy Pereira, Madison Nguyen, David Le Petrik, Jim Reprod Biol Endocrinol Review OBJECTIVE: To systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer. METHODS: An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion. RESULTS: The search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1). CONCLUSION: Liposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12958-023-01125-2. BioMed Central 2023-08-23 /pmc/articles/PMC10464441/ /pubmed/37612696 http://dx.doi.org/10.1186/s12958-023-01125-2 Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Son, Jin Sung
Chow, Ryan
Kim, Helena
Lieu, Toney
Xiao, Maria
Kim, Sunny
Matuszewska, Kathy
Pereira, Madison
Nguyen, David Le
Petrik, Jim
Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title_full Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title_fullStr Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title_full_unstemmed Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title_short Liposomal delivery of gene therapy for ovarian cancer: a systematic review
title_sort liposomal delivery of gene therapy for ovarian cancer: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464441/
https://www.ncbi.nlm.nih.gov/pubmed/37612696
http://dx.doi.org/10.1186/s12958-023-01125-2
work_keys_str_mv AT sonjinsung liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT chowryan liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT kimhelena liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT lieutoney liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT xiaomaria liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT kimsunny liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT matuszewskakathy liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT pereiramadison liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT nguyendavidle liposomaldeliveryofgenetherapyforovariancancerasystematicreview
AT petrikjim liposomaldeliveryofgenetherapyforovariancancerasystematicreview